RGEN vs RYTM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
RGEN shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
RYTM presents a classic high-growth biotech profile with a Piotroski F-Score of 4/9, indicating stable but not strong financial health. While the company boasts impressive gross margins (89.73%) and strong revenue growth (36.9%), it remains deeply unprofitable with a profit margin of -103.57%. The valuation is extremely stretched, evidenced by a Price/Sales ratio of 31.92 and a Price/Book of 42.87, suggesting the market has priced in significant future success. Despite a 'strong_buy' analyst consensus and a high target price, bearish insider activity and recent earnings misses temper the outlook.
Compare Another Pair
Related Comparisons
RGEN vs RYTM: Head-to-Head Comparison
This page compares Repligen Corporation (RGEN) and Rhythm Pharmaceuticals, Inc. (RYTM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.